Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOTRIO-2: Toripalimab + SBRT + Chemo for Chemo-Refractory TNBC
NCT07457359Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07457359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457359.